Current calls, week 14, 2023
Tips from KI Grants Office about current calls.
Swedish and Nordic calls
Residensprogrammet Eva De la Gardie - Svenska institutet i Paris och Franska Institutet i Stockholm
Sjätte utlysningen av residensprogrammet Eva De la Gardie vid Institut suédois à Paris ett bidrag från Institut français de Suède för resekostnader mellan Sverige och Frankrike samt för viss dagsersättning. Beloppet uppgår till 15 000 kronor för hela perioden. Residensprogrammet inkluderar grattis boende en av Svenska institutets gästbostäder i Paris. Vistelsen riktar sig till forskare som har avlagt doktorsexamen, forskar vid en svensk institution, exempelvis universitet eller forskningsinstitut (obs, inget nationalitetskrav) och har eller önskar få projekt kopplat till Frankrike.
Closing date: April 28, 2023
Forskningsbidrag - Familjen Kamprads stiftelse
Familjen Kamprads stiftelse utlyser 100 miljoner kronor till forskningsområdet ”Förbättrad livskvalitet för äldre” där forskare och samhällsaktörer med gemensamma krafter bidrar till äldres välbefinnande. Ansökan sker genom en tvåstegsprocess. Steg 1 öppnar onsdag 5 april. Stiftelsen välkomnar ansökningar inom alla ämnesdiscipliner från svenska universitet/högskolor, forskningsinstitut och regioner.
Closing date: May 4, 2023 at 16.00
Forskningsresidens - Svenska institutets och Svenska studenthuset
Svenska institutets och Svenska studenthuset vid Cité Universitaire de Paris öppnar utlysningen av Sophie Germains forskningsresidens i Paris från den 1 juni till den 30 juni 2023 (fasta datum). Residenset inkluderar fritt boende i ett rum, ett stipendium på 15 000 kronor som tackar resekostnader från Sverige till Frankrike och ett bidrag till levnadsomkostnader.
Closing date: May 15, 2023
Forskarstipendium - Svensk Förening för Övre Abdominell Kirurgi (SFÖAK)
SFÖAK annonserar forskarstipendier om 30 000 kr för att stöda kliniskt inriktad forskning inom övre abdominell kirurgi. Sökande måste vara medlem i SFÖAK för att kunna tilldelas stipendiet. För att godkännas av styrelsen krävs att man är legitimerad läkare med kirurgisk basspecialitet.
Closing date: May 31, 2023
Project grants in endocrinology and metabolism: Nordic region - Novo Nordisk Foundation
The Novo Nordisk Foundation calls for applications within basic and clinical research within the endocrine system and metabolism relating to cellular energy homeostasis. The objective is to promote Nordic research at the highest international level to carry out research projects of 1-3 years duration. The research activities applied for must take place at a university, hospital or other non-profit research institution in Denmark, Finland, Iceland, Norway or Sweden. Principal investigators are eligible to apply, i.e. experienced independent researchers who have already established their own research field and demonstrated the ability to conduct original research at a high international level, or researchers that are in the process of establishing themselves as independent researchers. The total amount applied for must be within the frame of DKK 300.000 and DKK 3 million.
Closing date: June 2, 2023
Project funding - MedTechLabs
MedTechLabs Research center set in collaboration between KTH Royal Institute of Technology (KTH), Karolinska Institutet (KI), and Region Stockholm announces call funding for programs focusing on world-leading demand-driven research in medical technology. The programmes should have the potential to deliver breakthrough developments within precision health and/or data-driven healthcare research, in areas characterized by high disease burden in society. Implementation of the programs should improve health care and increase its cost effectiveness. Projects must involve one program director from KI and one from KTH. MedTechLabs intends to support one to two programmes in the range of SEK 2–7 million per year per programme, during four to five years.
Closing date: June 5, 2023
Transnationella utlysningen inom det europeiska partnerskapet Transforming Health and Care Systems - Forte och Vinnova
Den första europeiska utlysningen inom partnerskapet Transforming Health and Care Systems (THCS JTC2023) fokuserar på framtidens vårdsystem. Utlysningen är ett samarbete mellan 21 länder och Europeiska kommissionen. Varje land finansierar sina egna aktörer i de internationella konsortierna. Svenskt deltagande möjliggörs genom ett samarbete mellan Forte och Vinnova. För denna utlysning har Forte en budget på cirka 15 miljoner SEK. Syftet med utlysningen är att fylla kunskapsluckor och stödja genomförandet av innovativa lösningar som ska bidra till att bättre organisera framtidens hälso- och omvårdssystem, med fokus på förebyggande och individanpassad vård och särskilt främja en bättre integrering och kontinuitet i vården, inklusive vård på distans när så är önskvärt/möjligt. Utlysningen består av projektbidrag, som kan löpa mellan 18 och 36 månader.
OBS: Ansökningar skickas in till THCS egen portal. En kort intresseanmälan måste även lämnas in via portalen senast den 23 maj. Ansökningar med svensk huvudsökande ska även skicka in sin ansökan till antingen Forte eller Vinnova.
Closing date: June 13, 2023
More information - Transforming Health and Care Systems
Mobility grant - SFVE-A program of the French Institute in Sweden
Svensk Fransk Vetenskap–Anslag (SFVE-A) program of the French Institute of Sweden offers mobility grant for French and Swedish researchers established in a Swedish or a French institution (e.g. university, research laboratory, etc.) the opportunity to participate in a mobility program between both countries. for a mobility in Sweden or in France. Mobility has to take place before the 10th of November 2023.
Closing date: August 31, 2023.
Börje Salming ALS-stiftelse utlyser anslag för forskare inom ALS-området
Börje Salming ALS-stiftelse kommer att ta emot ansökningar för finansiering av grundvetenskapliga och patientnära forskningsprojekt som är inriktade på studier av orsaker till ALS, utveckling av nya metoder för medicinsk behandling av sjukdomen samt projekt för innovativa lösningar som kan underlätta vid vård av ALS-patienter.
Closing date: August 1, 2023
European calls
Horizon Europe Pillar II – Health calls - two-stage
Note: These calls are part of the pilot on Blind Evaluation
Deadline: Stage 1 application: 19 September 2023. Stage 2 application: 11 April 2024
Please contact grantsoffice@ki.se if you plan to apply to one of the upcoming calls, especially if you aim to be the coordinator.
Access to health and care services for people in vulnerable situations
TOPIC ID: HORIZON-HLTH-2024-CARE-04-04-two-stage
Research and Innovation Actions
TOPIC ID: HORIZON-HLTH-2024-STAYHLTH-01-02-two-stage
Research and Innovation Actions
Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders
TOPIC ID: HORIZON-HLTH-2024-DISEASE-03-13-two-stage
Research and Innovation Actions
Tackling high-burden for patients, under-researched medical conditions
TOPIC ID: HORIZON-HLTH-2024-DISEASE-03-14-two-stage
Research and Innovation Actions
Comparative effectiveness research for healthcare interventions in areas of high public health need
TOPIC ID: HORIZON-HLTH-2024-DISEASE-03-08-two-stage
Research and Innovation Actions
TOPIC ID: HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage
Research and Innovation Actions
Pandemic preparedness and response: Adaptive platform trials for pandemic preparedness
TOPIC ID: HORIZON-HLTH-2024-DISEASE-03-11-two-stage
Research and Innovation Actions
Innovative non-animal human-based tools and strategies for biomedical research
TOPIC ID: HORIZON-HLTH-2024-TOOL-05-06-two-stage
Research and Innovation Actions
Personalised prevention of non-communicable diseases - addressing areas of unmet needs using multiple data sources
TOPIC ID: HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage
Research and Innovation Actions
Horizon Europe Pillar II – Health calls - single-stage
Deadline: 11 April 2024
Please contact grantsoffice@ki.se if you plan to apply to one of the upcoming calls, especially if you aim to be the coordinator.
Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)
TOPIC ID: HORIZON-HLTH-2024-IND-06-08
Research and Innovation Actions
Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators
TOPIC ID: HORIZON-HLTH-2024-IND-06-09
Coordination and Support Actions
Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness
TOPIC ID: HORIZON-HLTH-2024-DISEASE-08-12
Coordination and Support Actions
Bio-printing of living cells for regenerative medicine
TOPIC ID: HORIZON-HLTH-2024-TOOL-11-02
Research and Innovation Actions
Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential
TOPIC ID: HORIZON-HLTH-2024-DISEASE-08-20
Research and Innovation Actions
US calls
Federal Funding
CDMRP - Spinal Cord Injury Research Program (SCIRP)
Funded programs: Clinical Translation Research Award, Clinical Trial Award, Investigator-Initiated Research Award, Translational Research Award
Upcoming deadlines: LOI -May 24th, 2023; Full application – September 7rd, 2023.
Abstract: To be considered for funding, applications for the FY23 SCIRP Research Award must address a critical component of at least one of the Areas of Emphasis listed below, unless adequate justification for exception is provided.
The FY23 SCIRP Focus Areas are:
- Preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes;
- Therapeutics (devices and pharmacologic interventions) to stabilize SCI in the prehospital environment and during transport are encouraged;
- Identifying and validating biomarkers for diagnosis, prognosis, and evaluation of treatment efficacies;
- Investigating psychosocial issues relevant to people with SCI, their families, and/or their care partners.
Animal Models for Hepatitis B and C (R01 Clinical Trial Not Allowed), NIH
Funder's opportunity ID: RFA-AI-23-022
Upcoming deadlines: August 25, 2023
This Notice of Funding Opportunity (NOFO) encourages research focused on the development of convenient small animal models that will support infection and replication of HBV and/or HCV, ideally leading to the dichotomous outcomes of clearance and persistence. Alternatively, closely related surrogate virus-host systems or robust xenotransplantation models dually engrafted with human liver cells and human immune systems can be developed.
Defining Mechanisms of HIV Induced Inflammation and Immune Activation During Suppressive Antiretroviral Therapy (ART) (R01 Clinical Trial Not Allowed), NIH
Funder's opportunity ID: RFA-AI-23-018
Upcoming deadlines: August 2, 2023
This Notice of Funding Opportunity (NOFO) encourages research focused on defining the molecular mechanisms by which HIV proteins and/or nucleic acids induce inflammation, immune activation and HIV persistence during viral suppression as well as on developing novel therapeutic strategies to mitigate or eliminate the effects of continued HIV expression.
NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed), NIH
Funder's opportunity ID: PAR-23-132
Upcoming deadlines: standard due dates until May 8, 2026
The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. In addition to analysis of existing data, experimental or in silico work is required to validate the results of the proposed analysis , or to validate a newly developed analytic method. Projects aimed at understanding oral health disparities to inform strategies for improving health for all individuals are a priority. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.
NIDCR Research Grants for Analyses of Existing Genomics Data (R01) (Clinical Trial Not Allowed), NIH
Funder's opportunity ID: PAR-23-133
Upcoming deadlines: standard due dates until May 8, 2026
The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. In addition to analysis of existing data, experimental or in silico work is required to validate the results of the proposed analysis, or to validate a newly developed analytic method. Projects aimed at understanding oral health disparities to inform strategies for improving health for all individuals are a priority. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.
Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional), NIH
Funder's opportunity ID: PAR-23-148
Upcoming deadlines: standard due dates until May 8, 2026
The purpose of this Notice of Funding Opportunity (NOFO) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection.
Impacts of climate change across the cancer control continuum (R21, R01 Clinical Trial Optional), NIH
Funder's opportunity ID: PAR-23-152 (R21); PAR-23-153 (R01)
Upcoming deadlines: standard due dates until May 8, 2026
This Notice of Funding Opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.
Animal Models for Hepatitis B and C (R01 Clinical Trial Not Allowed), NIH
Funder's opportunity ID: RFA-AI-23-022
Upcoming deadlines: August 25, 2023
This Notice of Funding Opportunity (NOFO) encourages research focused on the development of convenient small animal models that will support infection and replication of HBV and/or HCV, ideally leading to the dichotomous outcomes of clearance and persistence. Alternatively, closely related surrogate virus-host systems or robust xenotransplantation models dually engrafted with human liver cells and human immune systems can be developed.
Foundation
The 2023 HD Human Biology Project, Hungtington’s Disease Society of America (HDSA), US
Upcoming deadlines: May 5, 2023 (LOI); July 6, 2023 (Full proposal).
Amount:
- $75,000/year ($50,000 salary support and $25,000 research budget)
- A one or two-year grant mechanism to provide support for young scientists and clinicians to work collaboratively with HD clinics from around the world
Eligibility:
- Preference given to young investigators (PhD and/or MDs) who are not yet independent
- Innovative ideas from non-scientists will also be accepted and encouraged
- Recipient must commit at least 50% effort to the project.
Abstract: The Huntington’s Disease Society of America (HDSA) is interested in sponsoring innovative lines of inquiry into human HD patient data that will shed light on the most proximal biological events caused by the mutant huntingtin gene. All research proposals must incorporate a patient-centric focus to understanding HD.
Research Grant on Antibody Drug Conjugates, Lung Cancer Research Foundation (LCRF), US
Upcoming deadlines: May 31, 2023
Amount: up to $270,000 in funding over a period of two years (disbursed at $135,000 per year).
Eligibility: Senior investigators with more than 10 years’ experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process. However, exceptions will be made for investigators with more than 10 years’ experience in other disease areas or topics.
Abstract: LCRF is collaborating with Daiichi Sankyo and AstraZeneca to fund innovative projects focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer. The LCRF – Daiichi Sankyo – AstraZeneca Research Grants will support those projects focused on one or more of the following topics that support research studies to develop further understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer and HER2 directed ADCs in HER2 mutant NSCLC and primary and acquired resistance to TROP2 directed and HER2 directed ADCs, including:
- Employment of state-of-the art technology to characterize ADC target expression on patient biopsies
- Development and evaluation of patient-derived xenograft models (PDX) from patients responsive and/or resistant to TROP2 directed or HER2 directed ADCs
- Discovery and/or validation of predictive biomarkers of TROP2 directed or HER2 directed ADCs efficacy in the lung cancer
- Prevalence of potential prognostic or predictive biomarkers from lung cancer cells and/or blood
- Co-expression of the identified biomarkers with other known biomarkers (eg actionable drivers, immune-related biomarkers, poor prognosis biomarkers)
- Evolution of the biomarkers pre-, during- and post-SOC treatment